Shanghai, China

Heping Li

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Skyline Therapeutics Limited. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Heping Li. Retrieved from https://idiyas.com/inventor/heping-li-55aerdmu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Heping Li: Innovator in Gene Therapy

Introduction

Heping Li is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of gene therapy, particularly through his innovative work on recombinant adeno-associated viruses.

Latest Patents

Heping Li holds a patent for "Recombinant Adeno-Associated Virus with Modified AAV Capsid Polypeptides." This patent represents a crucial advancement in the development of gene therapy techniques.

Career Highlights

Li is currently employed at Skyline Therapeutics Limited, where he continues to push the boundaries of genetic research and therapy. His work has garnered attention for its potential applications in treating various genetic disorders.

Collaborations

Heping Li collaborates with notable colleagues, including Yanqun Shu and Bing Wu, who contribute to his research endeavors and enhance the impact of his innovations.

Conclusion

Heping Li's contributions to gene therapy through his patent and work at Skyline Therapeutics Limited highlight his role as a key innovator in the field. His ongoing research promises to advance the understanding and treatment of genetic conditions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…